PTGX
NASDAQ · Biotechnology
Protagonist Therapeutics Inc
$137.18
-6.19 (-4.32%)
Performance
1D
—
1W
-5.30%
1M
-2.65%
3M
-8.55%
6M
+32.54%
1Y
+71.95%
YTD
+57.35%
Open$142.95
Previous Close$143.37
Day High$143.30
Day Low$135.03
52W High$160.81
52W Low$75.44
Volume—
Avg Volume645.3K
Market Cap9.26B
P/E Ratio111.65
EPS$1.04
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$142.20
Below
SMA 200
$117.49
Above
RSI (14)
59.6
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
20 analysts
Price Target
-77.8% upside
Current
$137.18
$137.18
Target
$30.47
$30.47
$24.78
$30.47 avg
$49.57
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 46.26M | 38.53M | 743.95M |
| Net Income | -130,833,774 | -98,068,124 | -91,860,800 |
| Profit Margin | -282.8% | -268.7% | -12.4% |
| EBITDA | -157,675,405 | -124,753,589 | -161,541,358 |
| Free Cash Flow | — | — | -86,698,990 |
| Rev Growth | +20.1% | +20.1% | +6.6% |
| Debt/Equity | — | — | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $288.24 | -2.24% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $460.28 | -3.80% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $167.57 | -3.96% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $542.50 | -1.19% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $902.90 | -2.98% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.66 | -2.74% | 28.8 | 23.28B |